8-KOther EventsExhibits & Filings

BOSTON SCIENTIFIC CORP 8-K Report, Corporate Update (Dec 14, 2020)

Filed December 14, 2020For Securities:BSX

Summary

Boston Scientific Corporation (BSX) announced a significant capital allocation decision on December 14, 2020, by initiating a new stock repurchase program. The Board of Directors authorized the repurchase of up to $1.0 billion of the Company's common stock. This move signals management's confidence in the company's valuation and its ability to generate free cash flow. Furthermore, the company provided an update on its previous buyback activity, disclosing that approximately $535 million was utilized in the fourth quarter of 2020 to repurchase 15.7 million shares, fully exhausting the remaining amount under its existing 2013 authorization. In addition to returning capital to shareholders, BSX also announced its intention to redeem $250 million of its 3.375% Notes due May 15, 2022. This debt reduction plan suggests a focus on optimizing the company's capital structure and potentially reducing interest expenses.

Key Highlights

  • 1New stock repurchase program authorized for up to $1.0 billion of common stock.
  • 2Completed the repurchase of approximately $535 million of common stock in Q4 2020, utilizing the full remaining amount under the prior authorization.
  • 3Repurchased 15.7 million shares in Q4 2020 at a weighted average price of $33.98.
  • 4Announced redemption of $250 million aggregate principal amount of 3.375% Notes due May 15, 2022.
  • 5Redemption is scheduled for December 29, 2020.
  • 6Indicates proactive capital management and commitment to shareholder returns.

Frequently Asked Questions

The new $1.0 billion stock repurchase program indicates that Boston Scientific's management believes its stock is undervalued and that the company has sufficient financial resources to return capital to shareholders. This is often viewed as a positive signal by investors, suggesting confidence in future earnings and cash flow generation.

Redeeming $250 million of these notes suggests that Boston Scientific may be looking to optimize its debt structure, potentially refinance at lower interest rates, or simply reduce its overall debt obligations and associated interest expense. It demonstrates a proactive approach to managing its balance sheet.

Stock repurchases reduce the number of outstanding shares. This can increase earnings per share (EPS) as the same net income is divided by fewer shares. It also reduces the supply of shares in the market, which can sometimes lead to an increase in the stock price. The company has also returned capital by fully utilizing its previous buyback authorization.

The company is authorizing up to $1.0 billion for new stock repurchases and is redeeming $250 million of its notes. In the fourth quarter of 2020, it already repurchased approximately $535 million worth of stock. This indicates a significant commitment to capital return and balance sheet optimization.